885698-94-2

Basic information

• Product Name: 1-Methyl-1H-indazole-4-boronic acid pinacol ester
• Synonyms: 1-Methyl-1H-indazole-4-boronic acid pinacol ester;1-Methylindazole-4-boronic acid pinacol ester;1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole;1-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (1-methyl-1H-indazol-4-yl)boronate;1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole
• CAS NO: 885698-94-2
• Molecular Formula: C₁₄H₁₉BN₂O₂
• Molecular Weight: 258.12
• Product Categories: Indazole;Organoborons
• Mol File: 885698-94-2.mol

Chemical Properties

• Melting Point: 84-89°C
• Boiling Point: 384.979°C at 760 mmHg
• Flash Point: 186.629°C
• Appearance: /
• Density: 1.111g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Methyl-1H-indazole-4-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-1H-indazole-4-boronic acid pinacol ester(885698-94-2)
• EPA Substance Registry System: 1-Methyl-1H-indazole-4-boronic acid pinacol ester(885698-94-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 885698-94-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
1-Methyl-1H-indazole-4-boronic acid pinacol ester is used as a key intermediate in the synthesis of pharmaceuticals for its ability to facilitate the creation of biologically active compounds. Its enhanced stability and reactivity due to the pinacol ester group make it a preferred choice in the development of new drugs.
Used in Agrochemical Development:
In the agrochemical industry, 1-Methyl-1H-indazole-4-boronic acid pinacol ester is used as a precursor in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals that can improve crop protection and yield.
Used in Organic Synthesis:
1-Methyl-1H-indazole-4-boronic acid pinacol ester is utilized as a reagent in various organic synthesis processes, where its boronic acid ester nature allows for specific types of chemical transformations, broadening the scope of synthetic organic chemistry.
Used in Biological Research:
1-Methyl-1H-indazole-4-boronic acid pinacol ester is also used as a research tool in biological studies, where it can help elucidate the mechanisms of biological processes, potentially leading to a better understanding of disease pathways and the development of targeted therapies.

InChI:InChI=1/C14H19BN2O2/c1-13(2)14(3,4)19-15(18-13)11-7-6-8-12-10(11)9-16-17(12)5/h6-9H,1-5H3

Upstream product

• 186407-74-9 4-bromoindazole 
• 360575-28-6 2-bromo-6-fluorobenzaldehyde 
• 365427-30-1 4-bromo-1-methyl-1H-indazole 
• 73183-34-3 bis(pinacol)diborane 
• 74-88-4 methyl iodide 

Relevant articles and documents

METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS

Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.